{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T01:42:37Z","timestamp":1778636557737,"version":"3.51.4"},"reference-count":111,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T00:00:00Z","timestamp":1600646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematology Reports"],"abstract":"<jats:p>Smoldering myeloma (SMM) is an asymptomatic stage characterized by bone marrow plasma cells infiltration between 10\u201360% in absence of myeloma-defining events and organ damage. Until the revision of criteria of MM to require treatment, two main prognostic models, not overlapping each other, were proposed and used differently in Europe and in US. Novel manageable drugs, like lenalidomide and monoclonal antibodies, with high efficacy and limited toxicity, improvement in imaging and prognostication, challenge physicians to offer early treatment to high-risk SMM. Taking advantage from the debates offered by SOHO Italy, in this review we will update the evidence and consequent clinical practices in US and Europe to offer readers a uniform view of clinical approach at diagnosis, follow-up and supportive care in the SMM setting.<\/jats:p>","DOI":"10.4081\/hr.2020.8951","type":"journal-article","created":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T16:56:35Z","timestamp":1600707395000},"page":"8951","source":"Crossref","is-referenced-by-count":3,"title":["How We Manage Smoldering Multiple Myeloma"],"prefix":"10.3390","volume":"12","author":[{"given":"Alessandra","family":"Romano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Cerchione","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Concetta","family":"Conticello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Di Raimondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,9,21]]},"reference":[{"issue":"24","key":"ref1","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1056\/NEJM198006123022405","article-title":"Smoldering multiple myeloma","volume":"302","author":"Kyle","year":"1980","journal-title":"The New England journal of medicine"},{"issue":"3","key":"ref2","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1182\/blood.V56.3.521.521","article-title":"Localized and indolent myeloma","volume":"56","author":"Alexanian","year":"1980","journal-title":"Blood"},{"issue":"1","key":"ref3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc"},{"issue":"12","key":"ref4","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"18","key":"ref5","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1056\/NEJMc1310911","article-title":"Treatment for high-risk smoldering myeloma","volume":"369","author":"Kristinsson","year":"2013","journal-title":"The New England journal of medicine"},{"issue":"25","key":"ref6","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N Engl J Med"},{"issue":"8","key":"ref7","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMoa01133202","article-title":"A long-term study of prognosis in monoclonal gammopathy of undetermined significance","volume":"346","author":"Kyle","year":"2002","journal-title":"N Engl J Med"},{"issue":"6","key":"ref8","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41408-018-0077-4","article-title":"Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria","volume":"8","author":"Lakshman","year":"2018","journal-title":"Blood Cancer J"},{"issue":"20","key":"ref9","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/blood-2014-09-568899","article-title":"Smoldering multiple myeloma","volume":"125","author":"Rajkumar","year":"2015","journal-title":"Blood"},{"issue":"2","key":"ref10","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41375-018-0206-x","article-title":"Subclonal evolution in disease progression from MGUS\/SMM to multiple myeloma is characterised by clonal stability","volume":"33","author":"Dutta","year":"2019","journal-title":"Leukemia"},{"issue":"1","key":"ref11","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1038\/s41467-018-05058-y","article-title":"Genomic patterns of progression in smoldering multiple myeloma","volume":"9","author":"Bolli","year":"2018","journal-title":"Nature Communications"},{"issue":"4","key":"ref12","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2017.345","article-title":"Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines","volume":"32","author":"Maura","year":"2018","journal-title":"Leukemia"},{"issue":"10","key":"ref13","doi-asserted-by":"crossref","first-page":"e465","DOI":"10.3324\/haematol.2018.209999","article-title":"The transcriptomic profile of CD138(+) cells from patients with early progression from smoldering to active multiple myeloma remains substantially unchanged","volume":"104","author":"Storti","year":"2019","journal-title":"Haematologica"},{"issue":"21","key":"ref14","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1200\/JCO.20.00437","article-title":"Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression","volume":"38","author":"Bustoros","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"ref15","doi-asserted-by":"crossref","first-page":"101152","DOI":"10.1016\/j.beha.2020.101152","article-title":"Highrisk smoldering myeloma versus early detection of multiple myeloma: Current models, goals of therapy, and clinical implications","volume":"33","author":"Kunacheewa","year":"2020","journal-title":"Best Pract Res Clin Haematol"},{"issue":"1","key":"ref16","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1038\/s41467-018-07305-8","article-title":"Microbiota-driven interleukin-17- producing cells and eosinophils synergize to accelerate multiple myeloma progression","volume":"9","author":"Calcinotto","year":"2018","journal-title":"Nature Communications"},{"issue":"5","key":"ref17","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s43018-020-0053-3","article-title":"Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma","volume":"1","author":"Zavidij","year":"2020","journal-title":"Nature Cancer"},{"issue":"2","key":"ref18","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1182\/blood.2019004537","article-title":"Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma","volume":"136","author":"Perez","year":"2020","journal-title":"Blood"},{"issue":"1","key":"ref19","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1038\/s41598-020-58859-x","article-title":"High-density neutrophils in MGUS and multiple myeloma are dysfunctional and immune-suppressive due to increased STAT3 downstream signaling","volume":"10","author":"Romano","year":"2020","journal-title":"Scientific Reports"},{"issue":"14","key":"ref20","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20143548","article-title":"Plasticity of High-Density Neutrophils in Multiple Myeloma is Associated with Increased Autophagy Via STAT3","volume":"20","author":"Puglisi","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"10","key":"ref21","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1182\/bloodadvances.2019000953","article-title":"Myeloma cells induce the accumulation of activated CD94low NK cells by cell-to-cell contacts involving CD56 molecules","volume":"4","author":"Barberi","year":"2020","journal-title":"Blood Adv"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"iv52","DOI":"10.1093\/annonc\/mdx096","article-title":"Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020","volume":"28","author":"Moreau","year":"2017","journal-title":"Annals of Oncology"},{"issue":"7","key":"ref23","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","article-title":"New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells","volume":"110","author":"Perez-Persona","year":"2007","journal-title":"Blood"},{"issue":"5","key":"ref24","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41408-020-0319-0","article-title":"The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?","volume":"10","author":"Sidiqi","year":"2020","journal-title":"Blood Cancer Journal"},{"issue":"22","key":"ref25","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1182\/bloodadvances.2018024794","article-title":"Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma","volume":"2","author":"Aljama","year":"2018","journal-title":"Blood Adv"},{"issue":"26","key":"ref26","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood.2019003382","article-title":"Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma","volume":"135","author":"Maia","year":"2020","journal-title":"Blood"},{"issue":"4","key":"ref27","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/ejh.12172","article-title":"Monoclonal gammopathy of undetermined significance: a new proposal of workup","volume":"91","author":"Mangiacavalli","year":"2013","journal-title":"Eur J Haematol"},{"issue":"5","key":"ref28","doi-asserted-by":"crossref","first-page":"E146","DOI":"10.1002\/ajh.25441","article-title":"Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group","volume":"94","author":"Bustoros","year":"2019","journal-title":"Am J Hematol"},{"issue":"Suppl 1","key":"ref29","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/ijlh.12504","article-title":"Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma","volume":"38","author":"van de Donk","year":"2016","journal-title":"Int J Lab Hematol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejim.2018.05.029","article-title":"Monoclonal gammopathies of unknown significance and smoldering myeloma: Assessment and management of the elderly patients","volume":"58","author":"Gonzalez-Calle","year":"2018","journal-title":"European Journal of Internal Medicine"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.clinbiochem.2019.09.004","article-title":"Reference change values of Mprotein, free light chain and immunoglobulins in monoclonal gammopathy","volume":"74","author":"Evliyaoglu","year":"2019","journal-title":"Clin Biochem"},{"issue":"6","key":"ref32","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1200\/JCO.2002.20.6.1625","article-title":"Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma","volume":"20","author":"Cesana","year":"2002","journal-title":"J Clin Oncol"},{"issue":"4","key":"ref33","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1046\/j.1365-2141.1997.1122939.x","article-title":"Prognostic features of asymptomatic multiple myeloma","volume":"97","author":"Weber","year":"1997","journal-title":"Br J Haematol"},{"issue":"4","key":"ref34","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/ccr3.2636","article-title":"Serum free light chains and multiple myeloma: Is it time to extend their application?","volume":"8","author":"Markovic","year":"2020","journal-title":"Clin Case Rep"},{"issue":"4","key":"ref35","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1046\/j.1365-2141.2003.04654.x","article-title":"Smoldering multiple myeloma: natural history and recognition of an evolving type","volume":"123","author":"Rosinol","year":"2003","journal-title":"Br J Haematol"},{"issue":"6","key":"ref36","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1038\/s41375-018-0013-4","article-title":"Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression","volume":"32","author":"Fernandez","year":"2018","journal-title":"Leukemia"},{"issue":"2","key":"ref37","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood-2007-08-108357","article-title":"Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma","volume":"111","author":"Dispenzieri","year":"2008","journal-title":"Blood"},{"issue":"4","key":"ref38","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/leu.2012.296","article-title":"Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma","volume":"27","author":"Larsen","year":"2013","journal-title":"Leukemia"},{"issue":"9","key":"ref39","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1200\/JCO.2009.25.5356","article-title":"Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma","volume":"28","author":"Hillengass","year":"2010","journal-title":"J Clin Oncol"},{"issue":"8","key":"ref40","doi-asserted-by":"crossref","first-page":"e599","DOI":"10.1038\/bcj.2017.78","article-title":"Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group","volume":"7","author":"Hillengass","year":"2017","journal-title":"Blood Cancer Journal"},{"issue":"5","key":"ref41","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s00256-018-3066-6","article-title":"Value of low-dose whole-body CT in the management of patients with multiple myeloma and precursor states","volume":"48","author":"Simeone","year":"2019","journal-title":"Skeletal Radiol"},{"issue":"2","key":"ref42","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12020486","article-title":"Imaging of Monoclonal Gammapathy of Undetermined Significance and Smoldering Multiple Myeloma","volume":"12","author":"Jamet","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"1","key":"ref43","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3324\/haematol.10554","article-title":"A prospective comparison of 18Ffluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma","volume":"92","author":"Zamagni","year":"2007","journal-title":"Haematologica"},{"issue":"1","key":"ref44","doi-asserted-by":"crossref","first-page":"101148","DOI":"10.1016\/j.beha.2020.101148","article-title":"Current and potential applications of positron emission tomography for multiple myeloma and plasma cell disorders","volume":"33","author":"Ulaner","year":"2020","journal-title":"Best Practice & Research Clinical Haematology"},{"issue":"1","key":"ref45","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1200\/JCO.1995.13.1.251","article-title":"Prognostic significance of magnetic resonance imaging in patients with asymptomatic multiple myeloma","volume":"13","author":"Moulopoulos","year":"1995","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"issue":"1","key":"ref46","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41467-017-00296-y","article-title":"Spatial genomic heterogeneity in multiple myeloma revealed by multiregion sequencing","volume":"8","author":"Rasche","year":"2017","journal-title":"Nature Communications"},{"issue":"5","key":"ref47","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20051248","article-title":"The Impact of Tumor Heterogeneity on Diagnostics and Novel Therapeutic Strategies in Multiple Myeloma","volume":"20","author":"Rasche","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"3","key":"ref48","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1148\/radiol.2020192621","article-title":"CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging","volume":"295","author":"Ulaner","year":"2020","journal-title":"Radiology"},{"issue":"38","key":"ref49","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.25402","article-title":"Volumetry based biomarker speed of growth: Quantifying the change of total tumor volume in whole-body magnetic resonance imaging over time improves risk stratification of smoldering multiple myeloma patients","volume":"9","author":"Wennmann","year":"2018","journal-title":"Oncotarget"},{"issue":"16","key":"ref50","doi-asserted-by":"crossref","first-page":"4756","DOI":"10.7150\/thno.33289","article-title":"Lack of Spleen Signal on Diffusion Weighted MRI is associated with High Tumor Burden and Poor Prognosis in Multiple Myeloma: A Link to Extramedullary Hematopoiesis?","volume":"9","author":"Rasche","year":"2019","journal-title":"Theranostics"},{"issue":"9","key":"ref51","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1001\/archinte.1988.00380090051014","article-title":"Prognosis of asymptomatic multiple myeloma","volume":"148","author":"Alexanian","year":"1988","journal-title":"Arch Intern Med"},{"issue":"1","key":"ref52","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0002-9343(93)90120-E","article-title":"Risk of disease progression in asymptomatic multiple myeloma","volume":"94","author":"Dimopoulos","year":"1993","journal-title":"Am J Med"},{"issue":"11","key":"ref53","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41408-018-0144-x","article-title":"Evolving changes in M-protein and hemoglobin as predictors for progression of smoldering multiple myeloma","volume":"8","author":"Atrash","year":"2018","journal-title":"Blood Cancer Journal"},{"issue":"4","key":"ref54","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/leu.2012.309","article-title":"Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease","volume":"27","author":"Kastritis","year":"2013","journal-title":"Leukemia"},{"issue":"1","key":"ref55","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1038\/s41467-018-05058-y","article-title":"Genomic patterns of progression in smoldering multiple myeloma","volume":"9","author":"Bolli","year":"2018","journal-title":"Nat Commun"},{"issue":"9","key":"ref56","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.3324\/haematol.2011.060780","article-title":"Genomic analysis of high-risk smoldering multiple myeloma","volume":"97","author":"Lopez-Corral","year":"2012","journal-title":"Haematologica"},{"issue":"22","key":"ref57","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1182\/bloodadvances.2017005934","article-title":"Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma","volume":"1","author":"Mailankody","year":"2017","journal-title":"Blood Adv"},{"issue":"34","key":"ref58","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1200\/JCO.2012.48.4923","article-title":"Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load","volume":"31","author":"Neben","year":"2013","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"issue":"8","key":"ref59","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1038\/leu.2013.86","article-title":"Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma","volume":"27","author":"Rajkumar","year":"2013","journal-title":"Leukemia"},{"issue":"1","key":"ref60","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1182\/blood-2013-07-515239","article-title":"Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120)","volume":"123","author":"Dhodapkar","year":"2014","journal-title":"Blood"},{"key":"ref61","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2015.124651","article-title":"Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120)","author":"Khan","year":"2015","journal-title":"Haematologica"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3389\/fonc.2019.00699","article-title":"Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives","volume":"9","author":"Romano","year":"2019","journal-title":"Front Oncol"},{"issue":"12","key":"ref63","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41408-018-0153-9","article-title":"Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC)","volume":"8","author":"Sanoja-Flores","year":"2018","journal-title":"Blood Cancer J"},{"issue":"3","key":"ref64","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/leu.2012.237","article-title":"High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma","volume":"27","author":"Bianchi","year":"2013","journal-title":"Leukemia"},{"issue":"3","key":"ref65","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41409-018-0264-8","article-title":"Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk- Adapted Therapy (mSMART) consensus statement","volume":"54","author":"Gonsalves","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"ref66","article-title":"International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials","author":"Costa","year":"2020","journal-title":"Leukemia"},{"issue":"12","key":"ref67","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1182\/bloodadvances.2018016998","article-title":"Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling","volume":"2","author":"Wu","year":"2018","journal-title":"Blood Adv"},{"issue":"9","key":"ref68","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.3324\/haematol.2015.124651","article-title":"Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120)","volume":"100","author":"Khan","year":"2015","journal-title":"Haematologica"},{"issue":"3","key":"ref69","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/ejh.12728","article-title":"Smoldering multiple myeloma risk factors for progression: a Danish population-based cohort study","volume":"97","author":"Sorrig","year":"2016","journal-title":"Eur J Haematol"},{"issue":"Suppl 1","key":"ref70","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/hon.2213","article-title":"Smoldering multiple myeloma","volume":"33","author":"Mateos","year":"2015","journal-title":"Hematological oncology"},{"issue":"10","key":"ref71","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1038\/leu.2016.123","article-title":"Bence Jones proteinuria in smoldering multiple myeloma as a predictor marker of progression to symptomatic multiple myeloma","volume":"30","author":"Gonzalez-Calle","year":"2016","journal-title":"Leukemia"},{"issue":"21","key":"ref72","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1182\/bloodadvances.2018021220","article-title":"Timing of treatment of smoldering myeloma: early treatment","volume":"2","author":"Mateos","year":"2018","journal-title":"Blood Adv"},{"issue":"2","key":"ref73","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1001\/jamaoncol.2015.23","article-title":"The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma","volume":"1","author":"Sigurdardottir","year":"2015","journal-title":"JAMA Oncol"},{"issue":"12","key":"ref74","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1182\/blood-2010-04-277566","article-title":"Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myelomarelated complications","volume":"116","author":"Bianchi","year":"2010","journal-title":"Blood"},{"issue":"24","key":"ref75","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1182\/blood-2009-11-252072","article-title":"Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study","volume":"115","author":"Kristinsson","year":"2010","journal-title":"Blood"},{"issue":"12","key":"ref76","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/s41408-017-0015-x","article-title":"Correlation between markers of bone metabolism and vitamin D levels in patients with monoclonal gammopathy of undetermined significance (MGUS)","volume":"7","author":"Lipe","year":"2017","journal-title":"Blood Cancer Journal"},{"issue":"1","key":"ref77","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/leu.2012.236","article-title":"A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma","volume":"27","author":"Witzig","year":"2013","journal-title":"Leukemia"},{"issue":"6","key":"ref78","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12061554","article-title":"Monoclonal Gammopathy of Undetermined Significance (MGUS)-Not So Asymptomatic after All","volume":"12","author":"Lomas","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"52","key":"ref79","doi-asserted-by":"crossref","first-page":"85764","DOI":"10.18632\/oncotarget.7969","article-title":"Granulocyte-like myeloid derived suppressor cells (G-MDSC) are increased in multiple myeloma and are driven by dysfunctional mesenchymal stem cells (MSC)","volume":"7","author":"Giallongo","year":"2016","journal-title":"Oncotarget"},{"issue":"21","key":"ref80","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20215459","article-title":"Monocytic Myeloid Derived Suppressor Cells in Hematological Malignancies","volume":"20","author":"Palumbo","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"7","key":"ref81","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1080\/14737159.2018.1470929","article-title":"PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy","volume":"18","author":"Romano","year":"2018","journal-title":"Expert Rev Mol Diagn"},{"issue":"8","key":"ref82","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1038\/leu.2016.84","article-title":"Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade","volume":"30","author":"Suen","year":"2016","journal-title":"Leukemia"},{"issue":"10","key":"ref83","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/s41419-019-1959-5","article-title":"TLR4 signaling drives mesenchymal stromal cells commitment to promote tumor microenvironment transformation in multiple myeloma","volume":"10","author":"Giallongo","year":"2019","journal-title":"Cell Death Dis"},{"issue":"8","key":"ref84","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12081999","article-title":"Inhibition of TLR4 Signaling Affects Mitochondrial Fitness and Overcomes Bortezomib Resistance in Myeloma Plasma Cells","volume":"12","author":"Giallongo","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"6","key":"ref85","doi-asserted-by":"crossref","first-page":"854","DOI":"10.3324\/haematol.2011.054015","article-title":"Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study","volume":"97","author":"Kristinsson","year":"2012","journal-title":"Haematologica"},{"issue":"6","key":"ref86","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.exphem.2015.02.005","article-title":"Monoclonal paraprotein influences baseline B-cell repertoire diversity and perturbates influenza vaccinationinduced B-cell response","volume":"43","author":"Tete","year":"2015","journal-title":"Exp Hematol"},{"issue":"2 Suppl 1","key":"ref87","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.tmrv.2007.01.001","article-title":"Guidelines on the use of intravenous immune globulin for hematologic conditions","volume":"21","author":"Anderson","year":"2007","journal-title":"Transfus Med Rev"},{"key":"ref88","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.blre.2019.01.001","article-title":"Management of infectious complications in multiple myeloma patients: Expert panel consensus-based recommendations","volume":"34","author":"Girmenia","year":"2019","journal-title":"Blood Rev"},{"key":"ref89","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.clim.2017.11.014","article-title":"Subcutaneous immunoglobulins in patients with multiple myeloma and secondary hypogammaglobulinemia: a randomized trial","volume":"191","author":"Vacca","year":"2018","journal-title":"Clin Immunol"},{"issue":"10","key":"ref90","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1007\/s00277-019-03786-9","article-title":"How to resolve a clinical and molecular puzzle: concomitant monoclonal gammopathy of undetermined significance (MGUS) with neutrophilia and clonal hematopoiesis of indeterminate potential (CHIP)","volume":"98","author":"Haefliger","year":"2019","journal-title":"Ann Hematol"},{"issue":"3","key":"ref91","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.thromres.2009.01.004","article-title":"The relationship between monoclonal gammopathy of undetermined significance and venous thromboembolic disease","volume":"125","author":"Cohen","year":"2010","journal-title":"Thromb Res"},{"issue":"10","key":"ref92","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1093\/annonc\/mdh385","article-title":"The risk of venous thromboembolic disease in patients with monoclonal gammopathy of undetermined significance","volume":"15","author":"Sallah","year":"2004","journal-title":"Ann Oncol"},{"issue":"3","key":"ref93","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/cncr.20405","article-title":"Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease","volume":"101","author":"Srkalovic","year":"2004","journal-title":"Cancer"},{"issue":"4 Suppl 4","key":"ref94","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1053\/j.seminhematol.2003.09.007","article-title":"Thalidomide in newly diagnosed multiple myeloma and overview of experience in smoldering\/indolent disease","volume":"40","author":"Rajkumar","year":"2003","journal-title":"Semin Hematol"},{"issue":"10","key":"ref95","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/ajh.21821","article-title":"Long-term results of singleagent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma","volume":"85","author":"Detweiler-Short","year":"2010","journal-title":"Am J Hematol"},{"issue":"8","key":"ref96","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1038\/sj.leu.2402183","article-title":"Thalidomide for previously untreated indolent or smoldering multiple myeloma","volume":"15","author":"Rajkumar","year":"2001","journal-title":"Leukemia"},{"issue":"8","key":"ref97","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1182\/blood-2008-06-164228","article-title":"Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease","volume":"112","author":"Barlogie","year":"2008","journal-title":"Blood"},{"issue":"5","key":"ref98","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1300439","article-title":"Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma","volume":"369","author":"Mateos","year":"2013","journal-title":"N Engl J Med"},{"issue":"10","key":"ref99","first-page":"751","article-title":"When to initiate treatment in smoldering multiple myeloma","volume":"15","author":"Mateos","year":"2017","journal-title":"Clin Adv Hematol Oncol"},{"issue":"9","key":"ref100","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1182\/blood-2015-10-662320","article-title":"Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis","volume":"127","author":"Paiva","year":"2016","journal-title":"Blood"},{"issue":"11","key":"ref101","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1200\/JCO.19.01740","article-title":"Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma","volume":"38","author":"Lonial","year":"2020","journal-title":"J Clin Oncol"},{"issue":"4","key":"ref102","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/bjh.15384","article-title":"Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study","volume":"182","author":"Jagannath","year":"2018","journal-title":"Br J Haematol"},{"issue":"7","key":"ref103","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/s41375-020-0718-z","article-title":"Daratumumab monotherapy for patients with intermediate-risk or highrisk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)","volume":"34","author":"Landgren","year":"2020","journal-title":"Leukemia"},{"issue":"13","key":"ref104","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1158\/1078-0432.CCR-18-3470","article-title":"Randomized, Double-Blind, Placebo- Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple Myeloma","volume":"25","author":"Brighton","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"15","key":"ref105","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1182\/bloodadvances.2019000300","article-title":"A pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis","volume":"3","author":"Manasanch","year":"2019","journal-title":"Blood Adv"},{"issue":"5","key":"ref106","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1080\/17474086.2020.1753502","article-title":"Monoclonal antibodies in newly diagnosed and smoldering multiple myeloma: an updated review of current clinical evidence","volume":"13","author":"Musto","year":"2020","journal-title":"Expert Rev Hematol"},{"issue":"6","key":"ref107","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.3324\/haematol.2013.103085","article-title":"A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma","volume":"99","author":"Korde","year":"2014","journal-title":"Haematologica"},{"issue":"2","key":"ref108","doi-asserted-by":"crossref","first-page":"e0171205","DOI":"10.1371\/journal.pone.0171205","article-title":"A single-arm, open-label, phase 2 clinical trial evaluating disease response following treatment with BI-505, a human anti-intercellular adhesion molecule-1 monoclonal antibody, in patients with smoldering multiple myeloma","volume":"12","author":"Wichert","year":"2017","journal-title":"PLoS One"},{"issue":"2","key":"ref109","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1177\/1534735416635742","article-title":"Addition of Rice Bran Arabinoxylan to Curcumin Therapy May Be of Benefit to Patients With Early-Stage B-Cell Lymphoid Malignancies (Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Stage 0\/1 Chronic Lymphocytic Leukemia): A Preliminary Clinical Study","volume":"15","author":"Golombick","year":"2016","journal-title":"Integr Cancer Ther"},{"issue":"5","key":"ref110","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/ajh.23159","article-title":"Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and curcumin: a randomized, double-blind placebocontrolled cross-over 4g study and an open-label 8g extension study","volume":"87","author":"Golombick","year":"2012","journal-title":"Am J Hematol"},{"issue":"6","key":"ref111","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1001\/jamaoncol.2015.2010","article-title":"Treatment With Carfilzomib- Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma","volume":"1","author":"Korde","year":"2015","journal-title":"JAMA Oncol"}],"container-title":["Hematology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.pagepress.org\/journals\/index.php\/hr\/article\/download\/8951\/8413","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.mdpi.com\/2038-8330\/12\/11\/8951\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T17:06:10Z","timestamp":1696698370000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2038-8330\/12\/11\/8951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,21]]},"references-count":111,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,9]]}},"alternative-id":["hr.2020.8951"],"URL":"https:\/\/doi.org\/10.4081\/hr.2020.8951","relation":{},"ISSN":["2038-8330"],"issn-type":[{"value":"2038-8330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,21]]}}}